Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Lung Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3460)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
J Clin Oncol - 2 days (New B)
osimertinib
Sensitive
:
A1
J Clin Oncol - 2d
osimertinib
Sensitive: A1 - Approval
J Clin Oncol - 2 days
osimertinib
Sensitive
:
A1
J Clin Oncol - 2 days - (New B)
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
J Clin Oncol - 2 days (New B)
osimertinib
Sensitive
:
A1
J Clin Oncol - 2d
osimertinib
Sensitive: A1 - Approval
J Clin Oncol - 2 days
osimertinib
Sensitive
:
A1
J Clin Oncol - 2 days - (New B)
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
TPX-0005
Sensitive: B - Late Trials
IASLC-TTLC 2023 - 5 days (New C3)
TPX-0005
Sensitive
:
B
IASLC-TTLC 2023 - 5d
TPX-0005
Sensitive: B - Late Trials
IASLC-TTLC 2023 - 5 days
TPX-0005
Sensitive
:
B
IASLC-TTLC 2023 - 5 days - (New C3)
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
BI 1810631
Sensitive: C2 – Inclusion Criteria
IASLC-TTLC 2023 - 5 days (New C3)
BI 1810631
Sensitive
:
C2
IASLC-TTLC 2023 - 5d
BI 1810631
Sensitive: C2 – Inclusion Criteria
IASLC-TTLC 2023 - 5 days
BI 1810631
Sensitive
:
C2
IASLC-TTLC 2023 - 5 days - (New C3)
ROS1 G2032R
Non Small Cell Lung Cancer
ROS1 G2032R
Non Small Cell Lung Cancer
TPX-0005
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
TPX-0005
Sensitive
:
C3
IASLC-TTLC 2023 - 5d
TPX-0005
Sensitive: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
TPX-0005
Sensitive
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
Chr del(9p) + PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
Chr del(9p) + PD-L1 overexpression
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
Immunotherapy
Resistant
:
C3
IASLC-TTLC 2023 - 5d
Immunotherapy
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
Immunotherapy
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + PTEN mutation
Non Small Cell Lung Cancer
EGFR mutation + TP53 mutation + PTEN mutation
Non Small Cell Lung Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5d
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + BRCA1 mutation
Non Small Cell Lung Cancer
EGFR mutation + TP53 mutation + BRCA1 mutation
Non Small Cell Lung Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5d
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + ARID1A mutation
Non Small Cell Lung Cancer
EGFR mutation + TP53 mutation + ARID1A mutation
Non Small Cell Lung Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5d
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + NF1 mutation
Non Small Cell Lung Cancer
EGFR mutation + TP53 mutation + NF1 mutation
Non Small Cell Lung Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5d
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
EGFR mutation + TP53 mutation + RB1 mutation
Non Small Cell Lung Cancer
EGFR mutation + TP53 mutation + RB1 mutation
Non Small Cell Lung Cancer
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5d
EGFR inhibitor
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
EGFR inhibitor
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
KEAP1 deletion + KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
KEAP1 deletion + KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
Immunotherapy
Resistant
:
C3
IASLC-TTLC 2023 - 5d
Immunotherapy
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
Immunotherapy
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
STK11 deletion + KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
STK11 deletion + KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days (New C3)
Immunotherapy
Resistant
:
C3
IASLC-TTLC 2023 - 5d
Immunotherapy
Resistant: C3 – Early Trials
IASLC-TTLC 2023 - 5 days
Immunotherapy
Resistant
:
C3
IASLC-TTLC 2023 - 5 days - (New C3)
EGFR G719A
Non Small Cell Lung Cancer
EGFR G719A
Non Small Cell Lung Cancer
amivantamab-vmjw
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days (New C4)
amivantamab-vmjw
Sensitive
:
C4
IASLC-TTLC 2023 - 5d
amivantamab-vmjw
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days
amivantamab-vmjw
Sensitive
:
C4
IASLC-TTLC 2023 - 5 days - (New C4)
MET F1200I
Lung Adenocarcinoma
MET F1200I
Lung Adenocarcinoma
TPX-0022
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days (New C4)
TPX-0022
Sensitive
:
C4
IASLC-TTLC 2023 - 5d
TPX-0022
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days
TPX-0022
Sensitive
:
C4
IASLC-TTLC 2023 - 5 days - (New C4)
MET H1094Y
Lung Adenocarcinoma
MET H1094Y
Lung Adenocarcinoma
TPX-0022
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days (New C4)
TPX-0022
Sensitive
:
C4
IASLC-TTLC 2023 - 5d
TPX-0022
Sensitive: C4 – Case Studies
IASLC-TTLC 2023 - 5 days
TPX-0022
Sensitive
:
C4
IASLC-TTLC 2023 - 5 days - (New C4)
SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression
Lung Cancer
SMARCA4 deletion + dMMR/MSI-H + PD-L1 underexpression
Lung Cancer
pembrolizumab
Resistant: C4 – Case Studies
IASLC-TTLC 2023 - 5 days (New C4)
pembrolizumab
Resistant
:
C4
IASLC-TTLC 2023 - 5d
pembrolizumab
Resistant: C4 – Case Studies
IASLC-TTLC 2023 - 5 days
pembrolizumab
Resistant
:
C4
IASLC-TTLC 2023 - 5 days - (New C4)
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
FDA - 1 week (New A1)
pembrolizumab
Sensitive
:
A1
FDA - 1wk
pembrolizumab
Sensitive: A1 - Approval
FDA - 1 week
pembrolizumab
Sensitive
:
A1
FDA - 1 week - (New A1)
ALK fusion
Lung Adenocarcinoma
ALK fusion
Lung Adenocarcinoma
alectinib
Sensitive: C2 – Inclusion Criteria
Anticancer Drugs - 1 week (New C4)
alectinib
Sensitive
:
C2
Anticancer Drugs - 1wk
alectinib
Sensitive: C2 – Inclusion Criteria
Anticancer Drugs - 1 week
alectinib
Sensitive
:
C2
Anticancer Drugs - 1 week - (New C4)
ROS1 fusion + KRAS G12C
Non Small Cell Lung Cancer
ROS1 fusion + KRAS G12C
Non Small Cell Lung Cancer
entrectinib
Resistant: C4 – Case Studies
NPJ Precis Oncol - 1 week (New C4)
entrectinib
Resistant
:
C4
NPJ Precis Oncol - 1wk
entrectinib
Resistant: C4 – Case Studies
NPJ Precis Oncol - 1 week
entrectinib
Resistant
:
C4
NPJ Precis Oncol - 1 week - (New C4)
EML4-ALK fusion
Lung Adenocarcinoma
EML4-ALK fusion
Lung Adenocarcinoma
alectinib
Sensitive: C4 – Case Studies
Anticancer Drugs - 1 week (New C4)
alectinib
Sensitive
:
C4
Anticancer Drugs - 1wk
alectinib
Sensitive: C4 – Case Studies
Anticancer Drugs - 1 week
alectinib
Sensitive
:
C4
Anticancer Drugs - 1 week - (New C4)
TMB-H + PD-L1 expression
Lung Cancer
TMB-H + PD-L1 expression
Lung Cancer
pembrolizumab
Sensitive: C4 – Case Studies
Medicine (Baltimore) - 1 week (New C4)
pembrolizumab
Sensitive
:
C4
Medicine (Baltimore) - 1wk
pembrolizumab
Sensitive: C4 – Case Studies
Medicine (Baltimore) - 1 week
pembrolizumab
Sensitive
:
C4
Medicine (Baltimore) - 1 week - (New C4)
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
crizotinib
Sensitive: A1 - Approval
Cancer Manag Res - 2 weeks (New C3)
crizotinib
Sensitive
:
A1
Cancer Manag Res - 2wk
crizotinib
Sensitive: A1 - Approval
Cancer Manag Res - 2 weeks
crizotinib
Sensitive
:
A1
Cancer Manag Res - 2 weeks - (New C3)
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
serplulimab
Sensitive: A1 - Approval
Henlius Press Release - 2 weeks (New A1)
serplulimab
Sensitive
:
A1
Henlius Press Release - 2wk
serplulimab
Sensitive: A1 - Approval
Henlius Press Release - 2 weeks
serplulimab
Sensitive
:
A1
Henlius Press Release - 2 weeks - (New A1)
No biomarker
Lung Non-Small Cell Squamous Cancer
No biomarker
Lung Non-Small Cell Squamous Cancer
penpulimab
Sensitive: A1 - Approval
Akeso Biopharma Press Release - 2 weeks (New A1)
penpulimab
Sensitive
:
A1
Akeso Biopharma Press Release - 2wk
penpulimab
Sensitive: A1 - Approval
Akeso Biopharma Press Release - 2 weeks
penpulimab
Sensitive
:
A1
Akeso Biopharma Press Release - 2 weeks - (New A1)
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
toripalimab
Sensitive: B - Late Trials
BioSpace - 2 weeks (New B)
toripalimab
Sensitive
:
B
BioSpace - 2wk
toripalimab
Sensitive: B - Late Trials
BioSpace - 2 weeks
toripalimab
Sensitive
:
B
BioSpace - 2 weeks - (New B)
EGFR T790M
Non Small Cell Lung Cancer
EGFR T790M
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
Future Oncol - 2 weeks (New B)
osimertinib
Sensitive
:
A1
Future Oncol - 2wk
osimertinib
Sensitive: A1 - Approval
Future Oncol - 2 weeks
osimertinib
Sensitive
:
A1
Future Oncol - 2 weeks - (New B)
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
alectinib
Sensitive: A1 - Approval
Cancer Manag Res - 2 weeks (New C3)
alectinib
Sensitive
:
A1
Cancer Manag Res - 2wk
alectinib
Sensitive: A1 - Approval
Cancer Manag Res - 2 weeks
alectinib
Sensitive
:
A1
Cancer Manag Res - 2 weeks - (New C3)
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
amivantamab-vmjw
Sensitive: A1 - Approval
Adv Ther - 2 weeks (New C3)
amivantamab-vmjw
Sensitive
:
A1
Adv Ther - 2wk
amivantamab-vmjw
Sensitive: A1 - Approval
Adv Ther - 2 weeks
amivantamab-vmjw
Sensitive
:
A1
Adv Ther - 2 weeks - (New C3)
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
ceritinib
Sensitive: A1 - Approval
Cancer Manag Res - 2 weeks (New C3)
ceritinib
Sensitive
:
A1
Cancer Manag Res - 2wk
ceritinib
Sensitive: A1 - Approval
Cancer Manag Res - 2 weeks
ceritinib
Sensitive
:
A1
Cancer Manag Res - 2 weeks - (New C3)
EGFR exon 19 deletion
Lung Adenocarcinoma
EGFR exon 19 deletion
Lung Adenocarcinoma
osimertinib
Sensitive: C1 - Off-label
Cancer Lett - 2 weeks (New D)
osimertinib
Sensitive
:
C1
Cancer Lett - 2wk
osimertinib
Sensitive: C1 - Off-label
Cancer Lett - 2 weeks
osimertinib
Sensitive
:
C1
Cancer Lett - 2 weeks - (New D)
EGFR exon 19 deletion + EGFR C797S
Lung Adenocarcinoma
EGFR exon 19 deletion + EGFR C797S
Lung Adenocarcinoma
osimertinib + anlotinib
Sensitive: C4 – Case Studies
Pharmacol Res - 2 weeks (New C4)
osimertinib + anlotinib
Sensitive
:
C4
Pharmacol Res - 2wk
osimertinib + anlotinib
Sensitive: C4 – Case Studies
Pharmacol Res - 2 weeks
osimertinib + anlotinib
Sensitive
:
C4
Pharmacol Res - 2 weeks - (New C4)
EGFR L860R
Lung Adenocarcinoma
EGFR L860R
Lung Adenocarcinoma
osimertinib
Sensitive: D – Preclinical
Cancer Lett - 2 weeks (New D)
osimertinib
Sensitive
:
D
Cancer Lett - 2wk
osimertinib
Sensitive: D – Preclinical
Cancer Lett - 2 weeks
osimertinib
Sensitive
:
D
Cancer Lett - 2 weeks - (New D)
MYCL expression
Non Small Cell Lung Cancer
MYCL expression
Non Small Cell Lung Cancer
MRT-2359
Sensitive: B - Late Trials
Monte Rosa Therap Press Release - 3 weeks (New B)
MRT-2359
Sensitive
:
B
Monte Rosa Therap Press Release - 3wk
MRT-2359
Sensitive: B - Late Trials
Monte Rosa Therap Press Release - 3 weeks
MRT-2359
Sensitive
:
B
Monte Rosa Therap Press Release - 3 weeks - (New B)
MYCN expression
Non Small Cell Lung Cancer
MYCN expression
Non Small Cell Lung Cancer
MRT-2359
Sensitive: B - Late Trials
Monte Rosa Therap Press Release - 3 weeks (New B)
MRT-2359
Sensitive
:
B
Monte Rosa Therap Press Release - 3wk
MRT-2359
Sensitive: B - Late Trials
Monte Rosa Therap Press Release - 3 weeks
MRT-2359
Sensitive
:
B
Monte Rosa Therap Press Release - 3 weeks - (New B)
EGFR exon 20 insertion
Non Small Cell Lung Cancer
EGFR exon 20 insertion
Non Small Cell Lung Cancer
mobocertinib
Sensitive: A1 - Approval
Takeda Press Release - 3 weeks (New A1)
mobocertinib
Sensitive
:
A1
Takeda Press Release - 3wk
mobocertinib
Sensitive: A1 - Approval
Takeda Press Release - 3 weeks
mobocertinib
Sensitive
:
A1
Takeda Press Release - 3 weeks - (New A1)
PBRM1 mutation
Non Small Cell Lung Cancer
PBRM1 mutation
Non Small Cell Lung Cancer
Immunotherapy
Resistant: C3 – Early Trials
Front Genet - 3 weeks (New C3)
Immunotherapy
Resistant
:
C3
Front Genet - 3wk
Immunotherapy
Resistant: C3 – Early Trials
Front Genet - 3 weeks
Immunotherapy
Resistant
:
C3
Front Genet - 3 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
BPI-7711
Sensitive: C3 – Early Trials
BMC Med - 3 weeks (New C3)
BPI-7711
Sensitive
:
C3
BMC Med - 3wk
BPI-7711
Sensitive: C3 – Early Trials
BMC Med - 3 weeks
BPI-7711
Sensitive
:
C3
BMC Med - 3 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
gefitinib + AB-329
Sensitive: C3 – Early Trials
Cancer Med - 3 weeks (New C3)
gefitinib + AB-329
Sensitive
:
C3
Cancer Med - 3wk
gefitinib + AB-329
Sensitive: C3 – Early Trials
Cancer Med - 3 weeks
gefitinib + AB-329
Sensitive
:
C3
Cancer Med - 3 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
osimertinib + MEDI9447
Sensitive: C3 – Early Trials
J Thorac Oncol - 3 weeks (New C3)
osimertinib + MEDI9447
Sensitive
:
C3
J Thorac Oncol - 3wk
osimertinib + MEDI9447
Sensitive: C3 – Early Trials
J Thorac Oncol - 3 weeks
osimertinib + MEDI9447
Sensitive
:
C3
J Thorac Oncol - 3 weeks - (New C3)
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression
Non Small Cell Lung Cancer
KRAS mutation + TP53 mutation + PD-L1 expression + PD-1 expression
Non Small Cell Lung Cancer
anlotinib + camrelizumab
Sensitive: C4 – Case Studies
Front Pharmacol - 3 weeks (New C4)
anlotinib + camrelizumab
Sensitive
:
C4
Front Pharmacol - 3wk
anlotinib + camrelizumab
Sensitive: C4 – Case Studies
Front Pharmacol - 3 weeks
anlotinib + camrelizumab
Sensitive
:
C4
Front Pharmacol - 3 weeks - (New C4)
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
atezolizumab
Sensitive: A1 - Approval
atezolizumab
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ramucirumab
Sensitive: A1 - Approval
ramucirumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
lorlatinib
Sensitive: A1 - Approval
lorlatinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
afatinib
Sensitive: A1 - Approval
afatinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
pembrolizumab
Sensitive: A1 - Approval
pembrolizumab
Sensitive
:
A1
ALK fusion
Non Small Cell Lung Cancer
ALK fusion
Non Small Cell Lung Cancer
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
KRAS G12C
Non Small Cell Lung Cancer
KRAS G12C
Non Small Cell Lung Cancer
sotorasib
Sensitive: A1 - Approval
sotorasib
Sensitive
:
A1
sotorasib
Sensitive: A1 - Approval
sotorasib
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
ALK positive
Non Small Cell Lung Cancer
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
brigatinib
Sensitive: A1 - Approval
brigatinib
Sensitive
:
A1
ROS1 fusion
Non Small Cell Lung Cancer
ROS1 fusion
Non Small Cell Lung Cancer
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
entrectinib
Sensitive: A1 - Approval
entrectinib
Sensitive
:
A1
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
tepotinib
Sensitive: A1 - Approval
tepotinib
Sensitive
:
A1
tepotinib
Sensitive: A1 - Approval
tepotinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
bevacizumab
Sensitive: A1 - Approval
bevacizumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
nivolumab + ipilimumab
Sensitive: A1 - Approval
nivolumab + ipilimumab
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
osimertinib
Sensitive: A1 - Approval
osimertinib
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
durvalumab
Sensitive: A1 - Approval
durvalumab
Sensitive
:
A1
EGFR T790M
Non Small Cell Lung Cancer
EGFR T790M
Non Small Cell Lung Cancer
lazertinib
Sensitive: A1 - Approval
lazertinib
Sensitive
:
A1
lazertinib
Sensitive: A1 - Approval
lazertinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
EGFR exon 19 deletion
Non Small Cell Lung Cancer
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
dacomitinib
Sensitive: A1 - Approval
dacomitinib
Sensitive
:
A1
MET exon 14 mutation
Non Small Cell Lung Cancer
MET exon 14 mutation
Non Small Cell Lung Cancer
capmatinib
Sensitive: A1 - Approval
capmatinib
Sensitive
:
A1
capmatinib
Sensitive: A1 - Approval
capmatinib
Sensitive
:
A1
PD-L1 overexpression
Non Small Cell Lung Cancer
PD-L1 overexpression
Non Small Cell Lung Cancer
cemiplimab
Sensitive: A1 - Approval
cemiplimab
Sensitive
:
A1
cemiplimab
Sensitive: A1 - Approval
cemiplimab
Sensitive
:
A1
RET fusion
Non Small Cell Lung Cancer
RET fusion
Non Small Cell Lung Cancer
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
EGFR mutation
Non Small Cell Lung Cancer
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
EGFR L858R
Non Small Cell Lung Cancer
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
gefitinib
Sensitive: A1 - Approval
gefitinib
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pemetrexed
Sensitive: A1 - Approval
pemetrexed
Sensitive
:
A1
pemetrexed
Sensitive: A1 - Approval
pemetrexed
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
ROS1 positive
Non Small Cell Lung Cancer
ROS1 positive
Non Small Cell Lung Cancer
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
crizotinib
Sensitive: A1 - Approval
crizotinib
Sensitive
:
A1
RET fusion
Non Small Cell Lung Cancer
RET fusion
Non Small Cell Lung Cancer
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login